Baillie Gifford & Co
RLAY icon

Baillie Gifford & Co’s Relay Therapeutics RLAY Stock Holding History

Baillie Gifford & Co’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-284,058
Closed -$1.85M – 292
2024
Q2 		$1.85M Sell
284,058
-69,168
-20% -$473K ﹤0.01% 245
2024
Q1 		$2.93M Sell
353,226
-20,370
-5% -$199K ﹤0.01% 245
2023
Q4 		$4.11M Sell
373,596
-20,854
-5% -$176K ﹤0.01% 243
2023
Q3 		$3.32M Sell
394,450
-16,858
-4% -$181K ﹤0.01% 243
2023
Q2 		$5.17M Sell
411,308
-4,355
-1% -$54.2K ﹤0.01% 242
2023
Q1 		$6.85M Buy
415,663
+1,141
+0.3% +$20.5K 0.01% 235
2022
Q4 		$6.19M Buy
414,522
+9,902
+2% +$190K 0.01% 241
2022
Q3 		$9.05M Buy
404,620
+184,998
+84% +$4.06M 0.01% 222
2022
Q2 		$3.68M Sell
219,622
-24,655
-10% -$528K ﹤0.01% 249
2022
Q1 		$7.31M Buy
244,277
+19,236
+9% +$467K 0.01% 243
2021
Q4 		$6.91M Buy
225,041
+11,952
+6% +$378K ﹤0.01% 257
2021
Q3 		$6.72M Buy
213,089
+20,568
+11% +$692K ﹤0.01% 255
2021
Q2 		$7.04M Buy
192,521
+21,235
+12% +$700K ﹤0.01% 252
2021
Q1 		$5.92M Buy
171,286
+91,354
+114% +$3.96M ﹤0.01% 249
2020
Q4 		$3.32M Sell
79,932
-5,584,989
-99% -$252M ﹤0.01% 238
2020
Q3 		$42.5M Buy
+5,664,921
New +$216M 0.03% 159

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Baillie Gifford & Co's RLAY Position: Q3 2024 in Review

Baillie Gifford & Co sold out of Relay Therapeutics (RLAY) in Q3 2024, closing a stake of 284,058 shares — an estimated $1.85M sold.

Baillie Gifford & Co first reported a position in RLAY in Q3 2020 and held it in 16 quarters. The position peaked at $42.5M in Q3 2020. 195 funds tracked by Wall St. Rank hold RLAY as of Q3 2024.

  • Baillie Gifford & Co reported no remaining Relay Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Baillie Gifford & Co sold 284,058 Relay Therapeutics shares in Q3 2024, an estimated $1.85M.
  • Baillie Gifford & Co first reported a position in Relay Therapeutics in Q3 2020 and held it in 16 quarters.
  • Baillie Gifford & Co's Relay Therapeutics position peaked at $42.5M in Q3 2020.
  • 195 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2024.

Based on Baillie Gifford & Co's 13F filing for Q3 2024, filed 5 Nov 2024.